Disorders of heart rhythm and conduction in dilated and hypertrophic cardiomyopathies

Idiopathic cardiomyopathies are characterized by diversity of clinical manifestations, among which heart rhythm abnormalities are the most common. The authors carried out qualitative and quantitative evaluations of heart rhythm abnormalities in patients with dilated and hypertrophic cardiomyopathies (DCMP, HCMP) and compared those abnormalities according to the data of daily ECG monitoring. Forty patients with DCMP and 30 with HCMP were examined. In 8 (25%) patients with DCMP and in 2 (6.7%) with HCMP, permanent atrial fibrillation was recorded. Among patients with sinus rhythm, supraventricular premature heart beats were found in 30 (96.8%) patients with DCMP and in 24 (85.7%) with HCMP. However, their number during 24 h exceeded 500 in 9 (29%) and in 7 (25%) patients, respectively. Supraventricular paroxysmal tachycardia (greater than or equal to 3 complexes at HR greater than or equal to 100/min) was recorded in 7 (22.6%) patients with DCMP and in 4 (14.3%) patients with HCMP. Ventricular premature heart beats were recorded in 38 (95%) patients with DCMP and in 21 (70%) patients with HCMP, polytopic in 31 (77.5% and 17 (56.7%), coupled in 227 (67.5%) and 10 (33.3%), ventricular paroxysmal tachycardia (greater than or equal to 3 complexes at HR greater than or equal to 100/min) in 22 (55%) and 5 (16.7%) patients, respectively. AV conduction abnormalities among patients with sinus rhythm were noted in DCMP and HCMP, in 12 (38.7%) and 1 (3.6%) cases, respectively. Thus, heart rhythm abnormalities are often encountered in both patients with DCMP and HCMP. However, in patients with DCMP, heart arrhythmias are graver and prognostically unfavourable.(ABSTRACT TRUNCATED AT 250 WORDS)     

243例心室晚电位检测的临床分析

本文对243例各种心脏病人采用体表信号平均心电图记录心室晚电位。结果表明:心绞痛及心肌缺血伴 VAs 病人 LPs 的检出阳性率(13/67)与无 VAs 病人(6/71)有显著差异(P<0.05);AMI 伴有 VAs 病人 LPs 检出阳性卒(10/18)与无 VAs 病人(2/9)有显著差异;CMI 伴有 VEs 病人 LPs 检出阳性率(7/18)而无VAs 病人仅检出 LP 阳性1例(1/8)心肌炎及原因不明的 VAs 者 LPs 检出阳性率亦较高(18/36)2例 LPs 阳性及1例 VF 史者发生猝死。     

抗心律失常肽与慢性心脏疾病的关系

目的。探讨慢性心律失常发生的常见疾病，如风湿性心脏病心房颤动、冠心病频发室性期前收缩及慢性心力衰竭患者血清中抗心律失常肽（AAP）含量的变化。方法采用高效液相法，利用高效液相色谱仪测定190例患者血清中AAP含量，并与正常同龄人血清中AAP含量比较。结果风湿性心脏病心房颤动、冠心病频发室性期前收缩、慢性心力衰竭患者血清AAP含量明显低于正常组（P〈0．001）。结论风湿性心脏病、冠心病、慢性心力衰竭都可造成血清中AAP含量下降，这可能是易诱发心律失常的原因之一。     

Electrophysiological Evaluation of Sustained Ventricular Tachyarrhythmias in Idiopathic Dilated Cardiomyopathy

Sustained ventricular tachyarrhythmias and sudden death are particularly prevalent in patients with idiopathic dilated cardiomyopathy (IDC). In contrast to patients with ischemic heart disease, the value of electrophysiological stimulation (EPS) in patients with IDC has not yet been established. To clarify the role of EPS in these patients, we studied 19 patients (58 +/- 11 years) with IDC who had symptomatic ventricular tachycardia (VT) or ventricular fibrillation (VF). The mean left ventricular ejection fraction was 26 +/- 9%. Ten patients had survived out-of-hospital cardiac arrest, eight had documented sustained monomorphic VT and one patient had non-sustained VT associated with syncope. Thirteen of the 19 patients (68%) had their clinical ventricular tachyarrhythmias induced at EPS (12 VT, 1 VF). In nine of 13 patients (69%), the arrhythmias were subsequently suppressed during serial electrophysiological drug testing. During 17 +/- 11 months of follow-up, 10/19 (53%) patients experienced recurrence of their arrhythmias and nine out of 19 (47%) patients died; six died suddenly and three secondary to heart failure. There was no difference in arrhythmia recurrence between patients with and without inducible ventricular tachyarrhythmias at initial study. Furthermore, suppression of arrhythmia during serial testing did not predict outcome; recurrences were observed in five out of nine patients whose arrhythmias were suppressed.(ABSTRACT TRUNCATED AT 250 WORDS)     

Frequency of spontaneous and inducible atrioventricular nodal reentry tachycardia in patients with idiopathic outflow tract ventricular arrhythmias

OBJECTIVES: We sought to assess the frequency of spontaneous or inducible atrioventricular nodal reentry tachycardia (AVNRT) in patients referred for radiofrequency ablation (RFA) of idiopathic outflow tract ventricular arrhythmias. BACKGROUND: In patients with no obvious heart disease, AVNRT and outflow tract ventricular tachycardia (VT) are the most frequently encountered supraventricular and ventricular tachycardias, respectively. An increased coexistence of the two arrhythmias has been recently suggested. METHODS: In 68 consecutive patients referred for RFA of an idiopathic ventricular outflow tract arrhythmia, a stimulation protocol including repeated bursts of rapid atrial pacing, up to triple atrial extrastimuli during sinus rhythm and rapid ventricular pacing was performed before and after isoproterenol infusion following RFA of the ventricular arrhythmia. In patients with inducible AVNRT, RFA of the slow pathway was performed. RESULTS: Of the 68 study patients, 17 (25%) had either spontaneous AVNRT documented prior to RFA of the ventricular arrhythmia (n = 4) or inducible AVNRT at the time of RFA of the ventricular arrhythmia (n = 13). AVNRT was induced by atrial pacing in 15 (88%) of 17 patients: in 3 patients without isoproterenol and in 12 patients during isoproterenol infusion. Uncomplicated RFA of the slow pathway was successfully achieved in all patients with inducible AVNRT. CONCLUSION: Spontaneous or inducible AVNRT is relatively common in patients with idiopathic outflow tract ventricular arrhythmias. Atrial stimulation, especially when performed after isoproterenol infusion plays a major role in AVNRT inducibility. Although we performed RFA of the slow pathway in patients with inducible AVNRT and no prior tachycardia documentation, the question whether this is mandatory remains unsettled.     

New ICD-Technologies: First Clinical Experience with Dual-Chamber Sensing for Differentiation of Supraventricular Tachyarrhythmias

Inappropriate ICD therapy for supraventricular arrhythmias remains an unsolved problem and may lead to serious clinical situations. Current algorithms for differentiation of supraventricular and ventricular arrhythmias are based on ventricular sensing solely and, therefore, lack semitivity and specificity. This preliminary analysis from a multicenter trial comprises data from the first 26 patients who received a Res-Q? Micron active-can ICD (Stdzer Intermedics) with a ventricular defibrillation lead and an additional bipolar lead for atrial sensing. Digitized atrial and ventricular waveform storage as well as interval charts from 102 induced and 30 spontaneous arrhythmia episodes were prospectively collected and analyzed with regard to appropriateness of ICD therapy. From all 132 arrhythmia episodes, high-quality stored dual-chamber intracardiac electrograms (JFXJM) could be retrieved for further analysis: in 40 (30%) episodes, atrial fibrillation (AF with rapid ventricular response 22, AF with VT9, AF with VF 9) was identified as the underlying intrinsic rhythm, and inappropriate ICD therapy was delivered in 4/22 (18%) episodes of AF with rapid ventricular response. In the remaining 92 (70%) episodes, sinus rhythm was the underlying atrial rhythm (SR with VT 13, SR with VF 79), and no inappropriate therapy was observed. Three of 22 (15%) high-energy shocks delivered for ventricular arrhythmias (VT 9, VF 9, rapid AF 4) terminated AF at the same time. In total, there were 3 complications (2 atrial lead dislodgments, I revision for bleeding). Both atrial lead dislodgments occurred in the 2 patients with passive-fixation leads compared to none in the 24 patients with active-fixation leads (p - 0.003). In conclusion, dual-chamber sensing and waveform storage of the new Res-Q? Micron offer very helpful diagnostic tools for the detection of inappropriate ICD-therapy. Placement of an additional atrial lead is safe and does not interfere with proper ICD function. However, for avoidance of atrial lead dislodgment, active fixation leads are recommended With the tested active-can lead configuration, the efficacy of successful atrial cardioversion by high-energy shocks delivered for ventricular arrhythmias seems to be low.     

Clinical results of an advanced SVT detection enhancement algorithm

INTRODUCTION: Supraventricular tachycardia (SVT) has many characteristics that are similar to ventricular tachycardia (VT). This presents a significant challenge for the SVT-detection algorithms of an implantable cardioverter defibrillator (ICD). A newly developed ICD, which utilizes a Vector Timing and Correlation algorithm as well as interval-based conventional SVT discrimination algorithms (Rhythm ID), was evaluated in this study. MATERIALS AND METHODS: This study was a prospective, multicenter trial that evaluated 96 patients implanted with an ICD at 21 U.S. centers. All patients were followed at 2 weeks, 1 month, and every 3 months post implant. A manual Rhythm ID reference vector was acquired prior to any arrhythmia induction. During testing, atrial tachyarrhythmias were induced first, followed by ventricular arrhythmia induction. Induced and spontaneous SVT and VT/ventricular fibrillation (VF) episodes recorded during the trial were annotated by physician investigators. RESULTS: The mean age of the patients implanted with an ICD was 67.3 +/- 10.8 years. Eighty-one percent of patients were male. The primary cardiovascular disease was coronary artery disease, and the primary tachyarrhythmia was monomorphic VT. Implementation of the Rhythm ID algorithm did not affect the VT/VF detection time. There were a total of 370 ventricular tachyarrhythmias (277 induced and 93 spontaneous) and 441 SVT episodes (168 induced and 273 spontaneous). Sensitivity for ventricular tachyarrhythmias was 100%, and specificity for SVT was 92% (94% and 91% for induced and spontaneous SVT, respectively). All patients had a successful manual Rhythm ID acquisition prior to atrial tachyarrhythmia induction. At the 1-month follow-up, the Rhythm ID references were updated automatically an average of 167.8 +/- 122.7 times. Stored Rhythm ID references correlated to patients' normally conducted rhythm 100% at 2 weeks, and 98% at 1 month. CONCLUSIONS: The Rhythm ID algorithm achieved 100% sensitivity for VT/VF, and 92% specificity for SVT. The manual and automatic Rhythm ID update algorithms successfully acquired references, and the updated references were highly accurate.     

Malignant Ventricular Arrhythmias in Chronic Chagasic Myocarditis

We studied 28 cases of chronic chagasic myocarditis (CCM) with frequent ventricular arrhythmias. Two-hundred and three conventional ECGs recorded during 3 months showed ventricular extrasystoles (VE) ranging between 0.2 and 6 per ten beats in 100%; multiform VE in 97.04%; couplets in 79.31%; ventricular tachycardia (VT) in 42.85%; and R on T in 21.67%. A 24-hour continuous recording showed that VE ranged between 3780 and 61733 (mean 16618 ± 2627); muitiform VE and couplets were present in 100% of patients, and VT was present in 78.5%. In 16 patients (group I) the frequency of VE was persistently high, without diurnal variation; 11 patients showed sustained reduction during sieeping hours and only one showed an increase during night sleep (group II). Even in group II, VE never disappeared for periods longer than 10 minutes. In five patients, four 24-hour recordings were obtained at weekly intervals, and in five other patients a second 24-hour recording was performed 10 to 24 months later. The remarkable frequency, persistence and low variability of ventricular arrhythmias in CCM suggest that such arrhythmias can be used as a most stable, reliable, but highly demanding model for testing the efficacy of antiarrhythmic drugs. (PACE, Vol. 5, March-April, 1982)     

缬沙坦对慢性充血性心力衰竭合并慢房颤患者室性心律失常的影响

目的观察短期应用缬沙坦对慢性充血性心力衰竭(CHF)合并慢房颤患者室性心律失常的影响。方法选择45例CHF合并慢房颤室性心律失常患者,均给予常规治疗,加用缬沙坦胶囊80 mg,每天1次,治疗8周。治疗前后分别行动态心电图检查,测量左室射血分数(LVEF),测定血清钾浓度。结果经8周缬沙坦治疗后室性早搏、室性心动过速发生率明显降低(P0.01);缬沙坦治疗前后LEVF比较差异有统计学意义(P0.05)。结论短期应用缬沙坦可能对CHF患者室性心律失常有效。     

Results of Electrophysiological Testing and Long-Term Follow-Up in Patients Sustaining Cardiac Arrest Only While Receiving Type IA Antiarrhythmic Agents

Therapeutic management of patients sustaining a cardiac arrest while receiving antiarrhythmic agents can be difficult since the role of the drug in possibly facilitating the arrhythmia is often difficult to define. To determine if the response to programmed stimulation could give insight into which patients may have experienced a drug-induced cardiac arrest, we studied 29 patients (61 +/- 9 years) with no prior history of sustained ventricular tachyarrhythmias (VT) who suffered a cardiac arrest only while receiving type Ia antiarrhythmic agents. Patients with documented myocardial infarction, acute ischemia, electrolyte abnormalities, or torsade de pointes were excluded from the study. Twenty-four patients had coronary artery disease with prior myocardial infarction (ejection fraction 28% +/- 9%) and five patients had idiopathic dilated cardiomyopathy (ejection fraction 31% +/- 6%). During baseline electrophysiological testing, 19 patients (66%) had inducible sustained ventricular arrhythmias: uniform VT, n = 14 (group I), polymorphic VT or ventricular fibrillation, n = 5 (group II). Ten patients (group III) had no inducible sustained ventricular arrhythmias. To determine if rechallenge with a type Ia agent could facilitate induction of a sustained ventricular arrhythmia in group III, eight patients underwent ten electrophysiological studies during therapy with either procainamide or quinidine. Only two patients developed sustained VT in response to programmed stimulation. Patients in groups I and II received therapy guided by electrophysiological testing, including antiarrhythmic agents alone (n = 8), subendocardial resection (n = 4), or an implantable cardioverter defibrillator (n = 7). Patients in group III received antiarrhythmic agents empirically (n = 3), or for treatment of atrial tachyarrhythmias (n = 2) or nonsustained VT (n = 1). In addition, four patients in group III received an implantable cardioverter defibrillator. During a mean follow-up of 28 +/- 27 months (range: 1 day-84 months) 13 patients died suddenly or received a defibrillator shock preceded by syncope or presyncope: group I: n = 5; group II: n = 2; group III: n = 6. In conclusion: (1) most patients sustaining a cardiac arrest only in the presence of type Ia antiarrhythmic agents have inducible sustained VT in the absence of antiarrhythmic agents, and (2) the risk of recurrent VT persists in patients without inducible sustained arrhythmias in the drug-free state, regardless of whether they manifest inducible arrhythmias after rechallenge with a type Ia agent.     

组织多普勒成像技术评估慢性房颤患者左室壁运动

目的 应用组织多普勒成像技术（DTI）探讨慢性房颤患者的室壁运动特点,为临床诊治提供重要的信息,方法,将研究分为三组,A组为18例正常对照,B组为15例心房大小正常的房颤患者,C组为16例心房扩大的房颤患者,所有患者均无严重瓣膜病或节段性室壁运动异常,采用HP SONOS 5500超声显像仪和脉冲DTI,分别在心尖四腔心切面和胸骨旁长轴切面测定左室侧壁和后壁收缩期峰值速度（VS）,舒张期峰值速度（VE）,心电图QRS波起始至收缩期峰值速度的平均时间T1,心电图QRS波起始至舒张期峰值速度的平均时间T2,平均心率为R－R,结果 （1）A组正常人均有舒张早期和晚期两个波峰（E峰和A峰）,B组和C组房颤患者均只有一个舒张期波峰（E峰）,（2）A组与B组这间的DTI测值差异均无显著性意义（均为P＞0．05）,（3）C组左室侧的VS显著小于A组（P＜0．05）,C组左室后壁的VS,VE均显著大于A组（P均＜0．05）,C组侧壁的T1／（R－R）^1/2,Ts/(R-R)1/2显著高于A组（P均＜0．05）,C组后壁的T1／（R－R）^1/2,T2/(R-R)^1/2与A组比较差异无显著性意义（P均＞0．05）,结论 左房增大的房颤患者左室壁在长轴方向收缩活动减弱,舒张期峰值速度延迟,在短轴方向舒缝活动增强,DTI技术能精确地定量分析房颤患者的室壁活动,可成为评价房颤患者心肌舒缩功能的无创伤性新方法。     

Ventricular Arrhythmias in Apparently Healthy Subjects

While it is assumed that the normal heart does not predispose to serious arrhyilimias, several conditions are now being recognized as being associated with short-lasting ventricular arrhythmias. It also becomes clear that idiopathic VT (or repetitive monomorphic VT) sometimes exists on the background of a compromised heart. Whether this dysfunction is due to the arrhythmia or vice versa is not evident. Finally, VF occurs in patients who, at a first glance, have no apparent heart disease, and it is then called idiopathic VF. These complex electrical abnormalities probably reflect disorders, which often are genetically determined. Recognition of these syndromes, often characterized by abnormal repolarization or a disturbed autonomic function is possible if appropriate techniques are used.     

Acute therapy of maternal and fetal arrhythmias during pregnancy

Atrial premature beats are frequently diagnosed during pregnancy. Supraventricular tachycardia (atrial tachycardia, atrioventricular nodal reentrant tachycardia, circus movement tachycardia) is diagnosed less frequently. For acute therapy, electrical cardioversion with 50 to 100 J is indicated in all unstable patients. In stable supraventricular tachycardia, the initial therapy includes vagal maneuvers to terminate tachycardias. For short-term management, when vagal maneuvers fail, intravenous adenosine is the first choice drug and may safely terminate the arrhythmia. Ventricular premature beats are also frequently present during pregnancy and are benign in most patients; however, malignant ventricular tachyarrhythmias (sustained ventricular tachycardia, ventricular flutter, or ventricular fibrillation) may occur. Electrical cardioversion is necessary in all patients who are hemodynamically unstable with life-threatening ventricular tachyarrhythmias. In hemodynamically stable patients, initial therapy with ajmaline, procainamide, or lidocaine is indicated. In patients with syncopal ventricular tachycardia, ventricular fibrillation, ventricular flutter, or aborted sudden death, an implantable cardioverter-defibrillator is indicated. In patients with symptomatic bradycardia, a pacemaker can be implanted using echocardiography at any stage of pregnancy. The treatment of the pregnant patient with cardiac arrhythmias requires important modifications of the standard practice of arrhythmia management. The goal of therapy is to protect the patient and fetus through delivery, after which chronic or definitive therapy can be administered.     

Significance of external cardioversion induced atrial tachyarrhythmias

External cardioversion is used to stop VT or VF in emergency. Supraventricular tachyarrhythmias are sometimes noted after cardioversion in patients known to be previously in sinus rhythm. The purpose of the study was to evaluate the significance of supraventricular tachyarrhythmias induced by external cardioversion. The study population consisted of 22 patients who developed supraventricular tachyarrhythmias after transthoracic cardioversion (300 J) delivered to stop a VT or VF induced by electrophysiological study. Defibrillation used monophasic waveform. Supraventricular tachyarrhythmias complicated 6% of cardioversions for VT; before cardioversion, all patients were in sinus rhythm. After cardioversion, three patients developed a paroxysmal reentrant supraventricular tachycardia (PSVT), which was stopped by atrial pacing. The remaining patients developed AF that lasted from 3 minutes to 24 hours (n = 4). One patient remained in AF. AF developed after a sinus pause or bradycardia, which was due to the interruption of VT or VF in nine patients or was noted just when VT or VF stopped (n = 10). The analysis of clinical data indicated that all three patients who presented a PSVT had a history of PSVT. Among patients who developed a sinus pause dependent AF, two had a history of AF. Among ten patients who developed AF at the time of cardioversion, three had a history of AF. During follow-up (1-9 years), no patient without a history of AF developed spontaneous AF, but patients with history of tachycardias had arrhythmia recurrences. The mechanism of cardioversion related tachycardias can be a pause related dispersion of atrial refractoriness or an adrenergic reaction induced by VT or VF, factors that precipitate arrhythmias in patients with history of atrial arrhythmias (one third of patients). In conclusion, supraventricular tachyarrhythmia is relatively frequent after external cardioversion for ventricular tachyarrhythmia, has no prognostic significance in patients without previous history of atrial arrhythmias, but in those with history of tachycardias is associated with a high risk of recurrence.     

Value of Serial Electropharmacological Testing in Managing Patients Resuscitated from Cardiac Arrest

Electrophysiologic studies were performed in 11 patients (9 men, 2 women; mean age: 59.9 yrs) who had survived an episode of cardiac arrest due to ventricular tachycardia (VT) or ventricular fibrillation. The purpose of the studies was to evaluate the usefulness of serial acute drug testing in selecting an effective chronic antiarrhythmic regimen. Ten of the patients were suffering from chronic ischemic heart disease with one or more previous myocardial infarctions while one had no evidence of structural heart disease. A ventricular aneurysm was present in four of them. During control electrophysiologic study, a sustained VT was induced by ventricular stimulation (single and double extrastimuli at various paced ventricular cycle lengths plus bursts of rapid ventricular pacing) in nine of the ten patients (90%) who were studied while not receiving antiarrhythmic drugs; a non-sustained VT was induced in one of them (10%). In three patients (30%) VT could be initiated only by right ventricular stimulation at a side different from the apex (outflow tract). No arrhythmia was observed in the only patient who was studied while taking amiodarone orally (400 mg/day for more than three months). During serial acute drug testing a totally effective drug regimen (successful in preventing the induction of any ventricular arrhythmia) was found in seven of the ten patients (70%) who underwent this procedure and a partially effective drug regimen (a sustained VT was no longer inducible; it was easier to interrupt and it was considerably slower) was found in two patients (20%). None of the nine patients who received chronic antiarrhythmic therapy based on the results of serial acute drug testing died suddenly during a mean follow-up of 14 months (range: 3-28) and only one had a recurrence of cardiac arrest. The latter, however, was taking antiarrhythmic drugs at a dosage less than that proved to be effective during electropharmacological testing. The only patient who refused serial acute drug testing and received an empiric antiarrhythmic therapy died suddenly at the 21st month of follow-up. These results indicate that serial electropharmacological testing is useful in selecting an effective long-term drug regimen in survivors of cardiac arrest.     

Transcutaneous Cardiac Pacing for Termination of Tachyarrhythmias

ALTAMURA, G., ET AL.: Transcutaneous Cardiac Pacing for Termination of Tachyarrhythmias. Transcutaneous cardiac pacing (TCP) was used for interruption of tachyarrhythmias in 31 patients: 20 with ventricular tachycardia (VT); eight with atrioventricular reentrant tachycardia (AVRT) and three had atrioventricular nodal tachycardia (AVNT). The stimulators used (Pace Aid 50/52) allow pacing at programmable rates (50–160 ppm) and output (10–200 mA at 20-msec pulse duration), when possible overdrive pacing was used. Short bursts of stimuli were delivered with increasing current intensity until interruption of the arrhythmia or to the maximum energy tolerated by the patient. VTs were interrupted in eight of the 20 patients: four of the six (67%) treated by overdrive pacing and four of the 14 (29%) were treated by underdrive pacing. Supraventricular tachycardias (SVT) were terminated in eight of the 11 patients: seven out of eight (88%) AVT, and one out of three AVNT (33%). We observed two cases of arrhythmia worsening: a VT acceleration and induction of ventricular fibrillation in a patient with AVNT. TCP was well tolerated by the majority of the patients. We conclude that TCP is an effective method for interruption of ventricular and supraventricular reentrant tachycardias, but the risk of arrhythmia worsening must be considered.     

Noninvasive Arrhythmia Risk Stratification in Idiopathic Dilated Cardiomyopathy: Design and First Results of the Marburg Cardiomyopathy Study

The Marburg Cardiomyopathy Study (MACAS) is a prospective, observational study designed to determine the value of the following potential noninvasive arrhythmia risk predictors in at least 200 patients with idiopathic dilated Cardiomyopathy (IDC) over a 5-year follow-up period: NYHA-class, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, left bundle branch block and atrial fibrillation on ECG, QT/JT dispersion on 12-lead ECG, signal-averaged ECG, ventricular arrhythmias and heart rate variability (HRV) on 24-hour Hotter ECG, baroreflex sensitivity, and microvolt T wave alternans during exercise. This article describes the findings among the first 159 patients with IDCs enrolled in MACAS until May 1998 (40 women, 119 men;age:49 ± 12 years; LVEF: 32 ± 10%). Twenty-nine patients (18%) had atrial fibrillation and 130 patients (82%) were in sinus rhythm. Patients with sinus rhythm were further stratified according to LVEF < 30% (n = 54) versus LVEF ≥ 50% (n = 76). Compared to patients with LVEF ≥ 30%, patients with LVEF < 30% more often had left bundle branch block (43% vs 25%, P < 0.05), nonsustained VT (44% vs 22%, P < 0.05), decreased HRV (SDNN: 95 ± 39 vs 128 ± 42 ms, P < 0.01), decreased baroreflex sensitivity (5.6 ± 4 vs 8.3 ± 6 ms/mmHg, P < 0.01), and T wave alternans (59% vs 37%, P < 0.05). The prognostic significance of these findings will be determined by multivariate Cox analysis at the end of a 5-year follow-up. Primary endpoints in MACAS are overall mortality and arrhythmic events (i.e., sustained VT or VF, or sudden cardiac death).     

Amplitude of Atrial Electrical Activity During Sinus Rhythm and During Atrial Flutter-Fibrillation

The onset of atrial flutter or fibrillation in a patient with a DDD pacemaker may result in sensing of the atrial arrhythmia and an inappropriate ventricular pacing response. In order to assess the potential of this problem, we evaluated the amplitude of atrial electrograms recorded from the right atrial appendage during sinus rhythm and during atrial flutter or fibrillation during 19 episodes in 18 patients. in 11 episodes of fibrillation and eight episodes of flutter, there was no difference in amplitude of either unipolar or bipolar atrial electrograms compared to that recorded during sinus rhythm (p > 0.05). In 14 of 19 episodes, the direction of depolarization of the bipolar electrogram did not change appreciably between sinus rhythm and the atrial arrhythmia. In summary, there is insufficient difference between amplitude of atrial depolarizations recorded during sinus rhythm and atrial flutter or fibrillation to be differentiated reliably by DDD pacemakers.     

Management of atrial fibrillation in patients with chronic obstructive pulmonary disease

Atrial fibrillation is the cardiac arrhythmia encountered most often in clinical practice. It is triggered by many conditions such as thyroid dysfunction, cardiac disease, alcohol, and pulmonary disease. Patients with chronic obstructive pulmonary disease (COPD) are susceptible to many insults that can lead to an acute deterioration superimposed on chronic disease. Changes in blood gases, abnormalities in pulmonary functions, and hemodynamic changes resulting from pulmonary hypertension can lead to the development of atrial fibrillation. Atrial fibrillation and COPD frequently coexist and complicate treatment of both conditions. The treatment of COPD exacerbation may include beta-adrenergic agonist and theophylline, which can precipitate atrial fibrillation with rapid ventricular response. Pharmacologic and electrical cardioversion may be ineffective in the management of atrial fibrillation in patients with COPD until respiratory decompensation has been corrected. This article focuses on the management of atrial fibrillation in patients with COPD.     

Intravenous Propafenone for Conversion of Atrial Fibrillation or Flutter to Sinus Rhythm: A Randomized, Placebo-controlled, Crossover Study

BACKGROUND: Propafenone has been claimed to be effective in converting atrial fibrillation and flutter to sinus rhythm; however, controlled clinical trials have reported variable results, and data about the safety of propafenone in the setting of heart failure are lacking. The aim of the present study was to evaluate the efficacy and safety of intravenous propafenone in converting atrial fibrillation and flutter to sinus rhythm. METHODS: Sixty patients with acute (<72 h) or chronic atrial fibrillation or flutter were included in a randomized, placebo-controlled, conditional cross-over study. Twenty eight patients, of whom 12 were in New York Heart Association class III and IV, had heart failure. Patients received intravenous propafenone (2 mg/kg in 10 minutes) and placebo subsequently at 1 hour intervals if sinus rhythm was not achieved. The patients' rhythms were continuously monitored for 1 hour and a 12-lead electrocardiogram, a 1-minute continuous rhythm strip and vital signs were recorded at baseline and at 15, 30, 45, and 60 minutes after the administration of each drug. RESULTS: Twenty of teh 59 patients (34%) treated with propafenone converted to sinus rhythm, while only 4 of the 50 patients (8%) treated with placebo converted (P <.001). Propafenone was more effective in patients with acute (<72 h) atrial fibrillation (64.5%). The conversion rate with propafenone was not significantly different from placebo in patients with atrial flutter and chronic atrial fibrillation (>72 h). Propafenone significantly decreased (P <.005 vs placebo) mean ventricular rate in nonresponders with a baseline heart rate of more than 100 beats/min. No clinically significant adverse effect occurred. CONCLUSIONS: We conclude that intravenous propafenone treatment is effective for converting acute atrial fibrillation; however, it seems unlikely to be beneficial in atrial flutter and chronic atrial fibrillation. Propafenone decreases ventricular rate in nonresponders, and a single dose of propafenone is relatively safe even in moderate-to-severe heart failure.